Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMEM132D antisense RNA 1 (TMEM132D-AS1)
- Target
- TMEM132D-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
TMEM132D antisense RNA 1 (TMEM132D-AS1) is a cytoplasmic long non-coding RNA (lncRNA) gene located on chromosome 12 (chr12:129109699-129113293, positive strand) with no protein-coding potential, classified as an antisense transcript to TMEM132D[3][5]. It is also known as LOC283352 and RP11-669N7.2, among other aliases[3][5]. TMEM132D-AS1 has been identified as significantly upregulated in osimertinib-resistant non-small cell lung cancer (NSCLC), where it modulates resistance by binding to miR-766-5p and increasing the expression of ENTPD1, contributing to enhanced cell proliferation and decreased apoptosis[2]. It may serve as a prognostic biomarker and a potential therapeutic target in the management of acquired resistance to targeted therapies in NSCLC[2].
- Other names
- LOC283352RP11-669N7.2ENST00000537367NONHSAT031930OTTHUMT00000399597.1GC12P129110GC12P129313GC12P130177GC12P131231GC12P133415ENSG00000249196
02
Mechanism of action
Regulation of drug resistance via miRNA sponging and target gene modulation (e.g., binding to miR-766-5p, upregulation of ENTPD1)[2]
03
Biological functions
Regulation of gene expressionModulation of cell proliferationRegulation of apoptosisCell cycle controlOther
04
Disease associations
CancerChemotherapy resistanceOther
05
Safety considerations
Potential for enhanced tumor proliferation and immune suppression when upregulated[2]
06
Interacting drugs
Osimertinib (associated with resistance in non-small cell lung cancer)[2]
07
Biomarkers
Prognostic biomarker for osimertinib resistance in non-small cell lung cancer[2]
Beyond the preview
Go deeper on TMEM132D antisense RNA 1 (TMEM132D-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMEM132D antisense RNA 1 (TMEM132D-AS1).